ElizabethHeritageCullMD

Oncology • Greenville, SC

Hematologic Oncology

Physician

Join to view full profile

Dr. Cull is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cull's full profile

Already have an account?

Office
65 International Dr
Greenville, SC 29615
Phone+1 864-987-7000

Fax+1 864-672-7852

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2009 - 2012
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2009

Certifications & Licensure

SC State Medical License 2015 - 2025
IL State Medical License 2009 - 2017
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

34 citations
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype.
Kelsie E. Oatmen, Elizabeth Cull, Francis G. Spinale
Nature Reviews. Cardiology. 2020-08-01
24 citations
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee
Cancers. 2021-08-15
93 citations
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.
Jessica K. Altman, Alfred Rademaker, Elizabeth H. Cull, Bing Bing Weitner, Yishai Ofran
Leukemia Research. 2013-09-01

Abstracts/Posters

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Elizabeth H. Cull, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
Elizabeth H. Cull, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Analyzing the Efficacy and Design Considerations of VR Environments to Manage Anxiety & Depression in AYA Cancer Patients
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019